Journal of Chemistry

Journal of Chemistry / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 539264 | https://doi.org/10.1155/2013/539264

R. Kalaichelvi, E. Jayachandran, "Quantitative Estimation of Sorafenib Tosylate Its Pure Form and in Its Tablet Formulation by RP-HPLC Method", Journal of Chemistry, vol. 2013, Article ID 539264, 3 pages, 2013. https://doi.org/10.1155/2013/539264

Quantitative Estimation of Sorafenib Tosylate Its Pure Form and in Its Tablet Formulation by RP-HPLC Method

Academic Editor: Tingyue Gu
Received21 Jun 2012
Accepted31 Jul 2012
Published16 Aug 2012

Abstract

A simple, accurate, specific reverse-phase, high-performance liquid chromatography method has been developed for the determination of sorafenib tosylate in its pure form and its tablets. In this method, sorafenib tosylate was eluted by isocratic mode using a Phenomenex Luna C18 column by a mobile phase composition of acetonitrile and water in the ratio of 82.5 : 17.5, v/v. The flow rate was 1.5 mL/min. The eluted drug was monitored at 265 nm and the method was found to be linear from 5 to 80 μg/mL. The method was validated by linearity, precision, accuracy, LOD, and LOQ. The accuracy report denotes that there is not any interference of additives used in the formulation.

1. Introduction

Sorafenib tosylate is chemically 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N-2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate. The drug was approved for the treatment of primary kidney cancer and advanced primary liver cancer. Sorafenib tosylate was estimated by RP-HPLC in human serum [1, 2]. It was estimated in bulk and in tablets by RP-HPLC [3], HPTLC [4], colorimetric estimation [5], and by UV method [6, 7]. The present work aims to develop a simple, precise, and accurate RP-HPLC method for the estimation of sorafenib tosylate in pure drug and in its tablet formulation.

2. Experimental Methods

Sorafenib tosylate pure drug was obtained as a gift sample from Natco pharma (Hyderabad, India). All the reagents used were HPLC grade.

2.1. Instrumentation

The HPLC experiment was carried out in a Shimadzu HPLC system equipped with Phenomenex Luna C18, 5 μm (4.6 × 250 mm) column, two LC-20AD pumps, SCL-10AVP system controller, Rheodyne injector with 50 μL loop, and SPD-20A UV-visible detector, and LC Solution software was used. All the reagents used were HPLC grade. The mobile phase was a mixture of acetonitrile and water (82.5 : 17.5, v/v) that was set at a flow rate of 1.5 mL/min.

2.2. Drug Stock Solution

Stock solution of sorafenib tosylate was prepared by dissolving accurately weighed 100 mg of the pure drug in 100 mL of mobile phase (final concentration, 1 mg/mL). The prepared stock solution was stored at 4°C and protected from light.

2.3. Calibration Curve

From the above stock solution, 10 mL was taken and diluted to 100 mL with mobile phase. Subsequent dilutions of this solution ranging from 5–80 μg/mL were made in 10 mL volumetric flasks. The solutions were filtered through 0.45 μm membrane filters and then 50 μL of filtrate was injected each time into the column at flow rate of 1.5 mL/min. Evaluation of the drug was performed with UV detector at 265 nm. Peak area was recorded for all peaks. A plot of peak area versus the respective concentration gives the calibration curve. The regression of drug concentration over the peak area was computed. Unknown samples were estimated by reference to this calibration curve.

2.4. Sample Preparation

Twenty tablets were weighed accurately and crushed to fine powder. From that, the amount of powder equivalent to 100 mg of sorafenib tosylate was weighed accurately and transferred to a 100 mL volumetric flask. Mobile phase (50 mL) was added and the mixture was sonicated for 10 min, for complete extraction of the drug, and the solution was diluted to volume with mobile phase. Then solution was centrifuged at 4000 rpm for 10 min, and the clear supernatant was collected and filtered through a 0.2 μm membrane filter. From this solution 10 mL was taken and diluted to 100 mL with mobile phase, again 4 mL was diluted to 10 mL to get 40 μg/mL solution, of which 50 μL was injected for HPLC analysis.

3. Results and Discussion

A typical chromatogram of sorafenib tosylate was shown in Figure 1. The retention time for sorafenib tosylate was 3.4 min. Flow rate was fixed at 1.5 ml/min, which gives tailing factor in the acceptable limit. The peak areas from such different concentrations of 5 to 80 μg/mL were calculated. A good linear relationship () was observed between the concentration drug and the respective peak area. The regression curve was constructed by linear regression fitting. The intraday and interday variations of the method were determined, a low coefficient of variation was observed. This shows that the present HPLC method is highly precise. To ensure accuracy of the method, recovery studies were carried out mixing a known quantity of drug with preanalyzed sample and the contents were reanalyzed by the proposed method. The recovery was about 99.95% to 100.23% (Table 2), indicating the high accuracy of the proposed HPLC method. The drug content in tablets was quantified using the proposed analytical method and the results are shown in Table 1.


SampleLabeled amount (mg/tablet)Amount found (mg/tablet)(%) label claima ± S.DPrecisionb
Inter-dayIntra-day

Sorafenib tablets200
199.7699.98 ± 0.2970.59980.2975

aAverage of six determinations.
b%RSD of six determinations.

SampleLabel claim (mg/tablet)Amount of drug
added ( 𝜇 g/mL)
Amount of drug
recovered ( 𝜇 g/mL)
Percentage recovery ± SDa

Sorafenib tablets2003232.08 1 0 0 . 2 3 ± 0 . 0 7 0
4039.92 9 9 . 8 1 ± 0 . 2 3 6
4847.98 9 9 . 9 5 ± 0 . 0 5 8

aMean of six determinations.

Chromatographic parameters such as peak asymmetry and capacity factor were found to be 1.03 and 0.921, respectively. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.133 and 0.403 μg/mL, respectively. The precision of the method was calculated in terms of the relative standard deviation. Low values of relative standard deviation indicated high precision and accuracy of the proposed method.

4. Conclusion

The developed RP-HPLC method was simple, sensitive, precise, and accurate and hence can be used in routine for the determination of sorafenib tosylate in pure as well as in tablets.

Conflict of Interests

The authors declare that there is no conflict of interests.

Acknowledgments

The authors are very thankful to Natco Pharma, Hyderabad, for providing pure drug and are also thankful to management of K. C. Reddy Institute of pharmaceutical sciences, Guntur, for providing necessary facilities to carry out this work.

References

  1. B. Blanchet, B. Billemont, J. Cramard et al., “Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice,” Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 4, pp. 1109–1114, 2009. View at: Publisher Site | Google Scholar
  2. W. J. Heinz, K. Kahle, A. Helle-Beyersdorf et al., “High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 1, pp. 239–245, 2011. View at: Publisher Site | Google Scholar
  3. S. VenkataRao, G. Ramu, A. Biksham Babu, T. Neeharika, and C. Rambabu, “Determination of sorafenib in bulk and tablet formulation by a new validated reverse phase high performance liquid chromatography,” Rasayan Journal of Chemistry, vol. 4, no. 2, pp. 477–480, 2011. View at: Google Scholar
  4. P. A. Shivaji and T. G. Pramila, “HPTLC Determination of Sorafenib tosylate in bulk drug and pharmaceutical dosage form,” International Research Journal of Pharmacy, vol. 3, no. 2, pp. 108–110, 2012. View at: Google Scholar
  5. R. Kalaichelvi and E. Jayachandren, “Spectrophotometric estimation of sorafenib in pharmaceutical preparation,” Journal of Pharmacy Research, vol. 4, no. 10, pp. 3707–3708, 2011. View at: Google Scholar
  6. R. Kalaichelvi and E. Jayachandren, “UV spectrophotometric estimation of sorafenib in pure and tablet dosage form,” Journal of Pharmacy Research, vol. 4, no. 10, pp. 3705–3706, 2011. View at: Google Scholar
  7. A. S. Powar, T. Pramila, G. P. Senthilkumar, T. Tamizh Mani, P. S. Mahadik, and S. B. Jagtap, “UV spectrometric determination of sorafenib tosylate in bulk and pharmaceutical dosage form,” American Journal of PharmTech Research, vol. 2, no. 1, pp. 356–361, 2012. View at: Google Scholar

Copyright © 2013 R. Kalaichelvi and E. Jayachandran. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views2844
Downloads1631
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.